Rankings
▼
Calendar
CLDX
Celldex Therapeutics, Inc.
$2B
FY 2015 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
+52.8% YoY
Gross Profit
$1M
26.8% margin
Operating Income
-$130M
-2363.9% margin
Net Income
-$127M
-2321.1% margin
EPS (Diluted)
$-19.66
Cash Flow
Operating Cash Flow
-$99M
Free Cash Flow
-$104M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$338M
Total Liabilities
$47M
Stockholders' Equity
$290M
Cash & Equivalents
$72M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$4M
+52.8%
Gross Profit
$1M
$185,000
+694.1%
Operating Income
-$130M
-$122M
-5.8%
Net Income
-$127M
-$118M
-7.7%
← FY 2014
All Quarters
Q1 2016 →
CLDX FY 2015 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena